# A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients

Study · id `cardio:ct-nct06254014` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06254014](<https://clinicaltrials.gov/study/NCT06254014>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06254014

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 270 participants.

## Technical summary

Registry record NCT06254014. Randomized; quadruple masking; primary purpose treatment. Start 2024-07-10 (actual); primary completion 2026-05-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 270 participants (enrolled count; ClinicalTrials.gov record NCT06254014, source copy `cardio:ctgov-nct06254014-2025-09-18`, retrieved 2026-10-26)
- Started: 2024-07-10 (actual) (ClinicalTrials.gov record NCT06254014, source copy `cardio:ctgov-nct06254014-2025-09-18`, retrieved 2026-10-26)
- Primary completion: 2026-05-01 (anticipated) (ClinicalTrials.gov record NCT06254014, source copy `cardio:ctgov-nct06254014-2025-09-18`, retrieved 2026-10-26)
- Completion: 2026-06-30 (anticipated) (ClinicalTrials.gov record NCT06254014, source copy `cardio:ctgov-nct06254014-2025-09-18`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06254014, source copy `cardio:ctgov-nct06254014-2025-09-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06254014-2025-09-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Exendin-4 Fc fusion protein injection
- Intervention (Drug): Exendin-4 Fc fusion protein injection
- Intervention (Drug): Placebo
- Lead sponsor: Beijing Dongfang Biotech Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 64d8ef9bbf860e14379dc4b1f466ba6a0488afd81d55f22aad48851a008cce41
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
